{"nctId":"NCT04231331","briefTitle":"Ertugliflozin for Functional Mitral Regurgitation","startDateStruct":{"date":"2020-11-04","type":"ACTUAL"},"conditions":["Mitral Valve Insufficiency","Left Ventricular Systolic Dysfunction"],"count":128,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Ertugliflozin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ertugliflozin"]}],"interventions":[{"name":"Ertugliflozin","otherNames":["Steglatro"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must agree to the study protocol and provide written informed consent\n* Outpatients ≥ 20 years of age, male or female\n* Non-diabetic or type2 DM patients with HbA1c 7.0-10.5%\n* Patients with secondary functional MR (stage B and C) and LV dysfunction\n\n  * Symptoms due to coronary ischemia or heart failure may be present but symptoms due to MR should be absent\n  * Normal mitral valve leaflets and chords\n  * Regional or global wall motion abnormalities with mild or severe tethering of leaflet\n  * MR whose ERO \\> 0.10 cm2 and which lasted \\> 6 months under medical treatment with a β-blocker and an ACE inhibitor (or ARB)\n  * 35% \\< LV ejection fraction \\< 50%\n* Dyspnea of NYHA functional class II or III\n* Titration of HF medications should be completed and patients must take a stable, optimized dose of a β-blocker and an ACE inhibitor (or ARB) for at least 4 weeks prior to study entry\n\nExclusion Criteria:\n\n* History of hypersensitivity or allergy to the study drug, drugs of similar chemical classes, or SGLT-2 as well as known or suspected contraindications to the study drug\n* Current use or prior use of a SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitor\n* Known history of angioedema\n* Any evidence of structural mitral valve disease, including prolapse of mitral leaflets and rupture of chords or papillary muscles\n* Current acute decompensated heart failure or dyspnea of NYHA functional class IV\n* Medical history of hospitalization within 6 weeks\n* Symptomatic hypotension and/or a SBP \\< 100 mmHg at screening\n* Estimated GFR \\< 45 mL/min/1.73m2\n* History of ketoacidosis\n* Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x upper limit of normal (ULN) at screening visit (Visit 0), history of hepatic encephalopathy, history of esophageal varices, or history of portacaval shunt.\n* Acute coronary syndrome, stroke, major CV surgery, PCI within 3 months\n* Substantial myocardial ischemia requiring coronary revascularization, a plan of coronary revascularization or mitral valve intervention within 1 year\n* Indication of cardiac resynchronization therapy, a plan of heart transplantation or implantation of cardiac resynchronization therapy\n* History of severe pulmonary disease\n* Significant aortic valve disease\n* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using a barrier method plus a hormonal method\n* Pregnant or nursing (lactating) women\n* Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change of EROA","description":"Change of effective regurgitant orifice area (EROA) of functional mitral regurgitation","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.12"},{"groupId":"OG001","value":"-0.05","spread":"0.06"}]}]}]},{"type":"SECONDARY","title":"Change of Regurgitant Volume","description":"Change of regurgitant volume of functional mitral regurgitation","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":"31.1"},{"groupId":"OG001","value":"24.6","spread":"14.3"}]}]}]},{"type":"SECONDARY","title":"Change of End-systolic Volume Index","description":"Left ventricular end-systolic volume was measured with the use of echocardiography. Left ventricular end-systolic volume index was obtained by dividing end-systolic volume by body surface area.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6","spread":"13.4"},{"groupId":"OG001","value":"-4.1","spread":"8.1"}]}]}]},{"type":"SECONDARY","title":"Change of End-diastolic Volume Index","description":"Left ventricular end-diastolic volume was measured with the use of echocardiography. Left ventricular end-diastolic volume index was obtained by dividing end-diastolic volume by body surface area.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","spread":"17.2"},{"groupId":"OG001","value":"-4.7","spread":"11.0"}]}]}]},{"type":"SECONDARY","title":"Change of NT-proBNP","description":"Change of NT-proBNP (N-terminal of the prohormone brain natriuretic peptide)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"126","spread":"1112"},{"groupId":"OG001","value":"-154","spread":"815"}]}]}]},{"type":"SECONDARY","title":"Change of Left Ventricular Global Longitudinal Strain","description":"Myocardial strain is a measure of percenage shortening of myocardium. Myocardial strain measurement was performed with a semiautomated alogithm using speckle-tracking echocardiogrphy. Measurements of eft ventricular global longitudinal strain were made in the 3 standard apical views and averaged.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.10","spread":"2.68"},{"groupId":"OG001","value":"-1.34","spread":"2.57"}]}]}]},{"type":"SECONDARY","title":"Change of LA End-systolic Volume Index","description":"Left atrial end-systolic volume was measured with the use of echocardiography. Left atrial end-systolic volume index was obtained by dividing end-systolic volume by body surface area.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"17.7"},{"groupId":"OG001","value":"-2.8","spread":"13.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":65},"commonTop":["Heart failure hospitalization"]}}}